CLINICAL_TRIALS
trial_result
· 2012-03-26
Clinical Trial Update: Phase IIIB Switching From Intravenous to Subcutaneous Study [Phase 3]
Summary
Phase IIIB study evaluating switching from intravenous to subcutaneous abatacept (Orencia) in rheumatoid arthritis completed; results posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2012-03-26